Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhenium-188 nanoliposome biodegradable alginate microsphere
- Development stage
- Preclinical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intra-arterial
01
Overview
Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM) is an investigational radiopharmaceutical designed for the treatment of solid organ tumors, particularly primary liver cancer (hepatocellular carcinoma) and secondary liver cancers such as metastatic colorectal cancer. The drug consists of biodegradable alginate microspheres containing thousands of nanoliposomes loaded with the radioisotope Rhenium-188. Upon intra-arterial administration via trans-arterial radioembolization (TARE), these microspheres embolize tumor-feeding blood vessels while delivering targeted beta radiation to tumor tissue. The dual mechanism involves both vascular occlusion and localized radiotherapy, leading to selective tumor necrosis. The use of a biodegradable carrier allows for eventual restoration of blood flow and safe clearance from the body. Plus Therapeutics is developing this therapy in preclinical stages, with technology licensed from The University of Texas Health Science Center at San Antonio[1][2][3][4][5][6].
- Other names
- 188rnl-bam
Beyond the preview
Go deeper on Rhenium-188 nanoliposome biodegradable alginate microsphere.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rhenium-188 nanoliposome biodegradable alginate microsphere.